Spain (ES)

Self-testing for contact allergy to hair dyes - a 5-year follow-up multicentre study (2018) Friis UF, Goosens A, Gimenez-Arnau AM, Liden C, Gimenez-Arnau E, White IR, Alfonso JH, et al. Journal article Induction of VEGF secretion from bone marrow stromal cell line (ST-2) by the dissolution products of mesoporous silica glass particles containing CuO and SrO (2018) Balasubramanian P, Salinas AJ, Sanchez-Salcedo S, Detsch R, Vallet-Regi M, Boccaccini AR Journal article, Original article Bioactive coatings on porous titanium for biomedical applications (2018) Dominguez-Trujillo C, Ternero F, Rodriguez-Ortiz JA, Heise S, Boccaccini AR, Lebrato J, Torres Y Journal article, Original article Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study (2018) Feagan BG, Panes J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, et al. Journal article Serum IP-10 levels and increased DPPIV activity are linked to circulating CXCR3+ T cells in cholestatic HCV patients (2018) Rau M, Schmitt J, Berg T, Kremer A, Stieger B, Spanaus K, Bengsch B, et al. Journal article Long-term safety of adalimumab in patients with moderate-to-severe ulcerative colitis: Interim results of a non-interventional registry, LEGACY (2018) Bossuyt P, Atreya R, Taxonera C, Hebuterne X, Isaacs K, Higgins PD, Lindsay J, et al. Conference contribution Pre-Treatment Tumor Growth Rate (TGR0) in Patients Diagnosed with Well-Differentiated Neuroendocrine Tumors (NETs) Treated with Systemic Therapies: Subgroup Analysis of the GREPONET Study (2018) Crona J, Lamarca A, Ronot M, Opalinska M, Lopez Lopez C, Pezzutti D, Vidal Trueba H, et al. Conference contribution Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Efficacy and Safety of Telotristat Ethyl in Patients With Carcinoid Syndrome Inadequately Controlled by Somatostatin Analogs: Analysis of the Completed TELESTAR Extension Period (2018) Hoersch D, Kulke MH, Caplin ME, Anthony LB, Bergsland E, Oberg K, Warner RRP, et al. Conference contribution